University Hospital Limerick

At University Hospital Limerick, a major focus is neoplasms research in breast cancer, especially early-stage, high-risk, and hormone receptor-positive disease. These studies are designed to improve outcomes by testing new treatment combinations, refining adjuvant care, and identifying which patients are most likely to benefit from chemotherapy or targeted therapy.

• Hormone receptor-positive, HER2-negative early breast cancer
• HER2-positive breast cancer with residual disease after surgery
• Triple-negative breast cancer and high-risk recurrence settings
• Personalized treatment decisions using risk and biomarker guidance

This work reflects an active effort to make breast cancer treatment more precise, effective, and tailored to individual risk.

The site also has strong activity in respiratory tract diseases and neoplasms, with multiple trials in non-small cell lung cancer. Research here explores new immunotherapy, targeted therapy, and combination approaches for advanced and early-stage disease, with the goal of improving survival and reducing recurrence after standard treatment.

• Advanced and metastatic non-small cell lung cancer
• KRAS G12C-mutant lung cancer
• Stage IV and post-surgery lung cancer
• Testing new therapies against established treatment options

These studies are helping advance treatment options for people with difficult-to-treat lung cancers.

Hemic and lymphatic diseases are a major research area at University Hospital Limerick, with studies in leukemia, lymphoma, and myeloma. The trials aim to improve disease control, deepen remission, and extend progression-free survival through newer targeted and immune-based therapies.

• Chronic lymphocytic leukemia and small lymphocytic lymphoma
• Mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma
• Acute myeloid leukemia and myelodysplastic syndromes
• Multiple myeloma, including newly diagnosed and relapsed disease

Overall, this research is focused on improving treatment effectiveness for a broad range of blood cancers.

Within its General and Colorectal Surgery department, the hospital is studying ways to reduce complications and improve recovery in colorectal cancer and elective bowel surgery. The research includes efforts to prevent surgical site infection and to support safer surgical care for patients undergoing major abdominal procedures.

• Colon cancer and rectal cancer
• Elective colorectal surgery
• Prevention of post-operative infection
• Improving surgical outcomes and recovery

This work combines cancer care with practical studies aimed at making surgery safer and more effective.

Research in male urogenital diseases at this site includes several studies in prostate cancer, especially advanced and metastatic disease. These trials are evaluating new hormonal and immune-based treatment strategies to delay progression and improve long-term disease control.

• Metastatic hormone-sensitive and hormone-naïve prostate cancer
• Advanced prostate cancer requiring systemic treatment
• Testing treatment strategies that balance effectiveness and quality of life
• Exploring improved outcomes for men with advanced disease

The research supports more individualized care for men facing advanced prostate cancer.

The trial portfolio also includes neoplasms research across several other solid tumors, including ovarian cancer, stomach cancer, oesophageal cancer, and malignant peritoneal neoplasm. These studies are designed to test newer therapies, improve disease-free survival, and better define maintenance or post-treatment strategies.

• Advanced ovarian, fallopian tube, and primary peritoneal cancers
• Gastrointestinal cancers such as stomach and oesophageal cancer
• Post-treatment maintenance and recurrence prevention
• Evaluating whether new treatments improve survival outcomes

This broad solid-tumor research shows a strong commitment to improving care across multiple cancer types at University Hospital Limerick.

Beyond cancer-focused studies, the site is also involved in bacterial infections and mycoses and cardiovascular diseases research linked to patient safety and supportive care. These trials look at preventing infection, reducing blood clot risk, and improving treatment tolerance in people living with serious illness.

• Surgical site infection prevention
• Venous thromboembolism in patients with cancer
• Supportive treatment for anemia and other treatment-related complications
• Improving safety alongside active disease treatment

These studies add an important supportive-care dimension to the broader clinical research program.